etretinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| retinol derivatives | 1116 | 54350-48-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 35 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.23 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 30, 1986 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D05BB01 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis |
| FDA CS | M0018962 | Retinoids |
| CHEBI has role | CHEBI:50176 | keratolytic drugs |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D007641 | Keratolytic Agents |
| FDA EPC | N0000175607 | Retinoid |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Psoriasis | indication | 9014002 | DOID:8893 |
| Oral lichen planus | off-label use | 235049008 | |
| Disorder of keratinization | off-label use | 277905003 | |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Corneal erosion | contraindication | 50792001 | |
| Corneal opacity | contraindication | 64634000 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Hypertrophy of bone | contraindication | 203514008 | DOID:205 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Drug-induced hepatitis | contraindication | 235876009 | |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Retinoic acid receptor RXR-gamma | Nuclear hormone receptor | AGONIST | DRUGBANK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019511 | VUID |
| N0000147631 | NUI |
| D00316 | KEGG_DRUG |
| 4019511 | VANDF |
| 4021061 | VANDF |
| C0015137 | UMLSCUI |
| CHEBI:4913 | CHEBI |
| CHEBI:50173 | CHEBI |
| CHEMBL464 | ChEMBL_ID |
| DB00926 | DRUGBANK_ID |
| D005050 | MESH_DESCRIPTOR_UI |
| 5282375 | PUBCHEM_CID |
| 7599 | IUPHAR_LIGAND_ID |
| 4658 | INN_ID |
| 65M2UDR9AG | UNII |
| 16818 | RXNORM |
| 117161 | MMSL |
| 2306 | MMSL |
| 4128 | MMSL |
| 4711 | MMSL |
| d01256 | MMSL |
| d03836 | MMSL |
| 001964 | NDDF |
| 004121 | NDDF |
| 108912002 | SNOMEDCT_US |
| 108914001 | SNOMEDCT_US |
| 386937001 | SNOMEDCT_US |
| 386938006 | SNOMEDCT_US |
| C0050559 | UMLSCUI |
| DB00459 | DRUGBANK_ID |
| 5530 | INN_ID |
| D017255 | MESH_DESCRIPTOR_UI |
| 5284513 | PUBCHEM_CID |
Pharmaceutical products:
None